Biohaven Pharma (BHVN) Misses Q2 EPS by 172c
Tweet
Share
E-mail
Biohaven Pharma (NYSE: BHVN) reported Q2 EPS of ($3.50), $1.72 worse than the analyst estimate of ($1.78).
For earnings history and earnings-related data on Biohaven Pharma (BHVN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Trump said he was unaware of his earnings from crypto
- Morgan Stanley Resumes OMV AG (OMV:AV) (OMVKY) at Equalweight
- HSBC Downgrades Stellantis NV (STLA:IM) (STLA) to Reduce
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
